Renaissance Group LLC Acquires Shares of 76,078 TransMedics Group, Inc. $TMDX

Renaissance Group LLC bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 76,078 shares of the company’s stock, valued at approximately $8,536,000. Renaissance Group LLC owned 0.22% of TransMedics Group at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of TMDX. Whittier Trust Co. of Nevada Inc. grew its holdings in TransMedics Group by 981.0% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after purchasing an additional 206 shares during the period. Salomon & Ludwin LLC bought a new stake in shares of TransMedics Group in the 3rd quarter worth approximately $28,000. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of TransMedics Group in the 3rd quarter worth approximately $40,000. First Horizon Corp bought a new position in TransMedics Group during the 3rd quarter valued at approximately $43,000. Finally, Elevation Point Wealth Partners LLC purchased a new position in TransMedics Group during the second quarter valued at $48,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Trading Up 4.2%

NASDAQ:TMDX opened at $135.06 on Friday. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43. TransMedics Group, Inc. has a 12 month low of $62.07 and a 12 month high of $156.00. The company has a market cap of $4.62 billion, a PE ratio of 54.68 and a beta of 2.06. The company has a 50 day simple moving average of $133.12 and a two-hundred day simple moving average of $124.36.

Insider Activity at TransMedics Group

In other news, CFO Gerardo Hernandez sold 920 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $139.62, for a total transaction of $128,450.40. Following the completion of the sale, the chief financial officer owned 15,064 shares of the company’s stock, valued at $2,103,235.68. This represents a 5.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David Weill sold 5,000 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total transaction of $693,200.00. Following the completion of the transaction, the director owned 12,134 shares in the company, valued at $1,682,257.76. This trade represents a 29.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 8,920 shares of company stock worth $1,257,310. 7.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TMDX. Jefferies Financial Group began coverage on TransMedics Group in a research note on Monday, October 13th. They issued a “buy” rating and a $145.00 target price on the stock. Needham & Company LLC increased their price objective on shares of TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Wall Street Zen lowered shares of TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Morgan Stanley upped their target price on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. Finally, Piper Sandler reiterated an “overweight” rating on shares of TransMedics Group in a report on Monday, December 22nd. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $144.25.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.